Innovation Pharmaceuticals Receives Pre-IND Response from

New Post Public Reply Private Reply Replies (2) Message Board
someconcerns
833
Innovation Pharmaceuticals Receives Pre-IND Response from FDA on COVID-19 Trial
BY GlobeNewswire
— 9:25 AM ET 11/02/2020

WAKEFIELD, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals ( IPIX
Loading... Loading...
) (“the Company”), a clinical stage biopharmaceutical company, announced today receipt of written feedback from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Company’s planned clinical trial for Brilacidin, a defensin-mimetic drug candidate, for the treatment of COVID-19. The FDA response completes the Pre-Investigational New Drug (Pre-IND) process.

The FDA provided feedback on clinical development plans for the evaluation of Brilacidin as a treatment for COVID-19. The Company is now incorporating this feedback and finalizing the trial protocol for its planned Phase 2, randomized, double-blind, placebo-controlled, multi-national study to evaluate the efficacy and safety of Brilacidin in hospitalized patients with COVID-19. Target enrollment for the trial is 120 patients. Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020.

“Getting to the point of being able to advance Brilacidin as a potential treatment for COVID-19 required an enormous amount of time, resources, and team effort,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals ( IPIX
Loading... Loading...
). “From the manufacturing of drug supply, to researching Brilacidin’s mechanisms of action in vitro against SARS-CoV-2 in infected cells, to now preparing and planning for the COVID-19 clinical study—was an extraordinary effort.”

Ehrlich added: “We are extremely grateful for the hard work of our employees, consultants and affiliated researchers. While no one can predict with certainty how Brilacidin will perform in clinical testing against COVID-19, we are optimistic based on the compelling preclinical antiviral data we have released and Brilacidin’s consistently successful results in other clinical trials. Our hope is Brilacidin for COVID-19 can be an important part of the solution to help rid the world of this deadly coronavirus.”

Brilacidin COVID-19 Preprint

The Company, based on pre-clinical research conducted in collaboration with George Mason University, has released a preprint, prior to formal peer review submission, demonstrating Brilacidin’s COVID-19 treatment potential. The preprint can now be downloaded on bioRxiv.org at the link below.

Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1

Global COVID-19 Cases and Mortality

An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website (http://www.ipharminc.com), and at the following link:
https://ipixcovid19tracker.com/

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 211

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
DJI Puts 3D Conservation Tools to Work Across Segovia

Updated Category News Views 146

Stone monuments do not care about marketing slogans; they care whether somebody notices the crack before winter gets hold of it. That is why DJI’s World Heritage 3D Conservation Initiative in Segovia lands as more than a shiny drone-company ceremony. The company gathered winning 3D fly-through work from its first initiative, but the useful bit was the case for turning...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 182

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 200

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 96

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 70

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 64

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 122

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading

Top 5 Most Recently Viewed Articles

Xometry Prepares for Financial Report Ahead of Market Opening

Updated Category News Views 175

Xometry Financial Results Announcement Overview Xometry, Inc. (NASDAQ: XMTR), recognized as a leading AI-powered marketplace for manufacturing services, is gearing up to announce its fourth quarter and full year 2024 financial results. The report is expected to be made available before trading opens on the market. This announcement represents a significant opportunity for...

Continue Reading
Warren Buffett's Surprising Bet on the RV Industry Pays Off

Updated Category News Views 1216

Warren Buffett's Unconventional Investment Journey Warren Buffett, known for his wisdom in investing, made a surprising decision that changed the game for Berkshire Hathaway Inc. He chose to invest in Forest River, an RV manufacturer, despite having little knowledge of the industry. This significant move, spearheaded by the late founder Pete Liegl, proved to be highly...

Continue Reading
BizClik Media Unveils September Editions of Key Industry Magazines

Updated Category News Views 201

BizClik Media Unveils September Editions of Key Publications This September, the latest editions of Supply Chain Digital, Procurement Magazine, and Manufacturing Digital have been published, featuring engaging interviews with industry leaders and experts from prominent companies. Spotlighting Industry Leaders This month's issues highlight a variety of thought-provoking...

Continue Reading
Ascletis Unveils Breakthrough Findings for ASC30 Injection

Updated Category News Views 210

Exciting Developments in Obesity Treatment with ASC30 In the realm of obesity management, Ascletis Pharma Inc. has made significant strides with their investigational drug ASC30, a promising GLP-1 receptor (GLP-1R) agonist designed for both oral and subcutaneous use. Preliminary results from their Phase Ib trial conducted in the U.S. indicate a fascinating half-life of 36...

Continue Reading
CBIZ Welcomes Kathy Raffa to Its Board of Directors

Updated Category News Views 204

CBIZ Strengthens Board with New Appointment CBIZ, Inc. (NYSE: CBZ), a prominent national professional services advisor, has recently announced the addition of Kathy Raffa to its Board of Directors. This strategic appointment, effective January 15, 2025, follows CBIZ's recent acquisition of the non-attest assets of Marcum. This move is seen as a testament to the...

Continue Reading